145 related articles for article (PubMed ID: 16950675)
1. Examination of stability of bone marrow blood RNA in the PAXgene tube.
Yamamoto T; Sekiyama A; Sekiguchi H; Yoshida T; Miyagi Y
Lab Hematol; 2006; 12(3):143-7. PubMed ID: 16950675
[TBL] [Abstract][Full Text] [Related]
2. Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization.
Müller MC; Merx K; Weisser A; Kreil S; Lahaye T; Hehlmann R; Hochhaus A
Leukemia; 2002 Dec; 16(12):2395-9. PubMed ID: 12454744
[TBL] [Abstract][Full Text] [Related]
3. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
Stock W; Yu D; Karrison T; Sher D; Stone RM; Larson RA; Bloomfield CD
Int J Oncol; 2006 May; 28(5):1099-103. PubMed ID: 16596225
[TBL] [Abstract][Full Text] [Related]
4. Preanalytical aspects of quantitative TaqMan real-time RT-PCR: applications for TF and VEGF mRNA quantification.
Isaksson HS; Nilsson TK
Clin Biochem; 2006 Apr; 39(4):373-7. PubMed ID: 16546153
[TBL] [Abstract][Full Text] [Related]
5. Differential gene expression profiles are dependent upon method of peripheral blood collection and RNA isolation.
Asare AL; Kolchinsky SA; Gao Z; Wang R; Raddassi K; Bourcier K; Seyfert-Margolis V
BMC Genomics; 2008 Oct; 9():474. PubMed ID: 18847473
[TBL] [Abstract][Full Text] [Related]
6. [Using real-time polymerase chain reaction to quantitate bcr-abl mRNA].
Liu JX; Liu JL; Wang GJ
Ai Zheng; 2006 Nov; 25(11):1447-9. PubMed ID: 17094919
[TBL] [Abstract][Full Text] [Related]
7. The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia.
Thörn I; Olsson-Strömberg U; Ohlsen C; Jonsson AM; Klangby U; Simonsson B; Barbany G
Haematologica; 2005 Nov; 90(11):1471-6. PubMed ID: 16266893
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of the PAXgene™ bone marrow RNA system for stabilizing total RNA.
Takeda M; Funato T; Ikemoto M; Nanmoku T; Urasaki Y; Iwatani Y
J Clin Lab Anal; 2015 Jan; 29(1):61-7. PubMed ID: 24687367
[TBL] [Abstract][Full Text] [Related]
9. Assessment of a new RNA stabilizing reagent (Tempus Blood RNA) for minimal residual disease in onco-hematology using the EAC protocol.
Prezeau N; Silvy M; Gabert J; Picard C
Leuk Res; 2006 May; 30(5):569-74. PubMed ID: 16209886
[TBL] [Abstract][Full Text] [Related]
10. Stabilization of mRNA expression in whole blood samples.
Rainen L; Oelmueller U; Jurgensen S; Wyrich R; Ballas C; Schram J; Herdman C; Bankaitis-Davis D; Nicholls N; Trollinger D; Tryon V
Clin Chem; 2002 Nov; 48(11):1883-90. PubMed ID: 12406972
[TBL] [Abstract][Full Text] [Related]
11. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
[TBL] [Abstract][Full Text] [Related]
12. Myogenin--a more specific target for RT-PCR detection of rhabdomyosarcoma than MyoD1.
Michelagnoli MP; Burchill SA; Cullinane C; Selby PJ; Lewis IJ
Med Pediatr Oncol; 2003 Jan; 40(1):1-8. PubMed ID: 12426678
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR.
Goh HG; Hwang JY; Kim SH; Lee YH; Kim YL; Kim DW
Transl Res; 2006 Nov; 148(5):249-56. PubMed ID: 17145570
[TBL] [Abstract][Full Text] [Related]
14. Impact of pre-analytical handling on bone marrow mRNA gene expression.
Breit S; Nees M; Schaefer U; Pfoersich M; Hagemeier C; Muckenthaler M; Kulozik AE
Br J Haematol; 2004 Jul; 126(2):231-43. PubMed ID: 15238145
[TBL] [Abstract][Full Text] [Related]
15. [The effect of matrix metalloproteinase-9 in granulocyte colony stimulation factor-induced stem cell mobilization].
Jin FY; Qiu LG; Li QC; Meng HX; Wang YF; Yu Z; Li Q; Han JL
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(42):2966-70. PubMed ID: 17288807
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
17. Real-time quantitative RT-PCR for human telomere elongation reverse transcriptase in chronic myeloid leukemia.
Gil ME; Coetzer TL
Leuk Res; 2004 Sep; 28(9):969-72. PubMed ID: 15234574
[TBL] [Abstract][Full Text] [Related]
18. Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.
Lundán T; Juvonen V; Mueller MC; Mustjoki S; Lakkala T; Kairisto V; Hochhaus A; Knuutila S; Porkka K
Haematologica; 2008 Feb; 93(2):178-85. PubMed ID: 18223279
[TBL] [Abstract][Full Text] [Related]
19. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
[TBL] [Abstract][Full Text] [Related]
20. Snapshot assessment of RNA-expression in severely burned patients using the PAXgene Blood RNA system: a pilot study.
Landes J; Langer S; Kirchhoff C; Schuetz C; Joneidi-Jafari H; Stegmaier J; Mutschler W; Biberthaler P
Burns; 2008 Mar; 34(2):197-204. PubMed ID: 17644265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
